Cerba Lancet Africa signs strategic partnership with international Clinical Laboratories in Ethiopia
- The partnership* illustrates Cerba HealthCare’s strategy to support long term health response locally and increase patient access to a broader range of laboratory testing across the continent
- International Clinical Laboratories (ICL) will leverage the world-class expertise range of Cerba HealthCare and its existing pan-African network Cerba Lancet Africa to sustainably meet the diagnostic tool expectations of patients, physicians and hospitals nationwide.
Johannesburg (South Africa) and Addis-Ababa (Ethiopia), 29th September 2022 - Cerba Lancet Africa, a benchmark in the field of medical diagnosis in Africa, today announced it has signed a strategic partnership with International Clinical Laboratories (ICL) Ethiopia, the leading private clinical pathology laboratory in the country serving more than 3 million patients over the past 17 years.
Cerba Lancet Africa is majority owned by the French group Cerba HealthCare, benefiting from a unique positioning on the whole value chain of medical diagnosis: alongside a worldwide presence through its expertise in clinical pathology for clinical trials, the Group has sound positions in Europe and Africa thanks to its historical activities in routine and specialty clinical pathology. Cerba HealthCare set foot on the African continent in 2019 where it operates today in 15 countries under the Cerba Lancet Africa umbrella, providing access to accurate diagnosis and high-quality care to more almost 3 million people yearly.
In Ethiopia, ICL stands as the reference player in clinical pathology with unparalleled experience and reputation. Its strong presence all over the country allowed the ICL’s team to play a critical role in handling the COVID-19 pandemic, which has exposed vulnerabilities of the numerous health systems across the globe and specifically the African one, together with the need for increased testing and diagnostic services.